Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

News SummaryMost relevantAll newsSector news 

Pfizer Inc. : Pfizer Gets Positive Opinion from EMA on Leukemia Drug Bosutinib

share with twitter share with LinkedIn share with facebook
share via e-mail
01/18/2013 | 02:46pm CEST
   By Saabira Chaudhuri 

Pfizer Inc. (>> Pfizer Inc.) said the European Medicines Agency (EMA) issued a positive opinion about the conditional marketing authorization of its cancer drug bosutinib in the European Union for the treatment of adult patients with certain types of leukemia.

Pfizer said the positive opinion was adopted by the Committee for Medicinal Products for Human Use and relates to chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor and for whom imatinib, nilotinib and dasatinib aren't considered appropriate treatment options.

Conditional approvals in the EU are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit.

Bosutinib is an oral, once-daily, kinase inhibitor, which limits cancer cell growth by inhibiting certain signaling pathways.

Pfizer noted that chronic myelogenous leukemia accounts for 15% of all leukemia cases and that, despite the availability of existing treatments for the condition, there remains a need for additional treatment options.

"We believe that bosutinib, if approved by the European Commission, would represent an important option for patients with CML who have progressed on prior treatment and are not candidates for alternative treatments," said Mace Rothenberg, senior vice president of clinical development and medical affairs at the Pfizer Oncology Business Unit. "We believe many doctors and CML patients will find this treatment, if approved, to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen."

Shares were flat at $26.83 in recent premarket trading. The stock has risen 22% in the past 12 months.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER INC
01:15a PFIZER : Ex-Oppenheimer & Co. worker pleads guilty to insider trading
10/24 ASTELLAS PHARMA : FDA Approves Supplemental New Drug Application for XTANDI (enz..
10/21 PFIZER : FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamid..
10/21 CHEMOCENTRYX : Appoints Henry A. McKinnell, Jr. to Board of Directors
10/20 PFIZER : Patent Application Titled "Sildenafil Sublingual Spray Formulations" Pu..
10/20 PFIZER : Presents Promising New Immunotherapy Combination Data With INLYTA® axit..
10/20 PFIZER : CDC Advisory Committee on Immunization Practices Votes to Recommend New..
10/20 PFIZER : CDC Advisory Committee on Immunization Practices Votes to Recommend New..
10/19 PFIZER : Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B S..
More news
Sector news : Pharmaceuticals - NEC
09:08a Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
10/25 ChemChina ready for concessions to clinch delayed Syngenta deal in 2017 - sou..
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Financials ($)
Sales 2016 52 982 M
EBIT 2016 19 366 M
Net income 2016 10 639 M
Debt 2016 28 244 M
Yield 2016 3,69%
P/E ratio 2016 17,82
P/E ratio 2017 14,56
EV / Sales 2016 4,23x
EV / Sales 2017 3,93x
Capitalization 195 799 M
More Financials
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 38,7 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%195 799
JOHNSON & JOHNSON10.94%311 781
ROCHE HOLDING LTD.-16.53%198 222
PFIZER INC.0.00%195 799
NOVARTIS AG-14.06%191 921
MERCK & CO., INC.17.29%171 305
More Results